Swiss Pharmaceutical Giant Novartis announced that it plans to build a $ 1.1 billion research hub in San Diego as part of an investment of $ 23 billion in US operations over the next five years.
The investment will create nearly 1,000 new jobs in Novartis, and the United States plans to build seven new facilities in the United States, “the major Novartis pharmaceuticals for the United States will be made in the United States,” the company said.
The news said that the pharmaceutical industry prepared for potential tariffs on drugs imported into the United States so far, and President Donald Trump exempted medicines, but this week, pharmaceutical tariffs will be “very soon.”
Novartis did not respond to the request of the Union Treborn on Thursday about the timing of the announcement related to Trump’s tariffs.
Novartis transactions also recorded significant investments in the regional life sciences, and the company announces dismissal Reduction of research and real estate footprintsAfter a high fashionability of medical investment.
The new San Diego Hub will be charged at the center of Novartis West Coast Biomedical Research and is a “latest research facility” that focuses on developing future pharmaceuticals.
The company is scheduled to open between 2028 and 2029 and said that there is a second R & D center of Novartis in the United States. Other research hubs are located in the home base of the company in Massachusetts Cimbridge and Basel, Switzerland.
Novartis has not disclosed a place to establish a new research center, how big or how much it will be used.
Joshua OHL, chief executive director of the market analysis of the real estate tracker, said, “This is good news for San Diego and talks with San Diego’s identity as a core life science market for San Diego.
In recent years, real estate investments in this scale have been rare. OHL has made the last regional real estate promise in the $ 1 billion area he recalls. IQHQ’s downtown RADD development Or 66 purchases of Blackstone 2021 Apartment Complex.
The therapeutic focus of a global pharmaceutical company is cancer, immunology, neuroscience, cardiovascular, kidney and metabolism. One of the well -known products of Novartis includes a groundbreaking treatment for heart failure called ENTRESTO.
VAS Narasimhan, CEO of Novartis, said, “As a company headquartered in Switzerland, which has a significant existence in the United States, we will be able to completely bring the supply network and major technology platforms to the United States to support the strong growth prospects of the United States.” And reflects the regulatory environment. “
Tim Scott, president and CEO of Biocom California, headquartered in San Diego, said that the company’s investment in the community is “very interesting.”
Scott said in an e -mail, “This is evidence of the strengths of the life science industry across California.” Local talent pools are unmatched by other, and the highly cooperative life science community of San Diego can provide cross -moisture to promote further innovation. The local builder also knows how to build a quality facility that meets the exact demands of life science companies. ”
San Diego has a history of attracting large pharmaceutical companies at the core of science near Torrey Pines, Sorrento Mesa and Carmel Valley. Companies such as PFIZER and ELI Lilly have established San Diego’s world -renowned scientists, research and development campuses close to universities to access talent and new innovation.
Mark Cafferty, CEO of San Diego Regional Economic Development Corp., thought Novartis would have an effort to reinvest in San Diego. But news about plans for a $ 1 billion research hub is welcome.
“The rumors were heard and the rumors and hopes that San Diego could see new investments in Novartis, and today’s announcement was made with amazing surprises in the size of the investment and clear emphasis on research and innovation in the region.
Cafferty suspects that not only is it his speculation, but also a plan to bring a new research facility to San Diego is in a hurry to bring a new research facility to San Diego with efforts to start STEEP’s STEEP.
“It would not be surprised if a lot of things that happened at the federal level could make decisions, and the study of San Diego actually led to the growth of San Diego’s biotechnology and life science for a long time.
The new facility not only leads to job creation of Novartis, but also has a ripple effect beyond its company, Capperty is suspicious.
“This will mean a new job in the actual facility where the research is carried out,” he said. “But due to the nature of work, new jobs will continue to come out through small businesses in a community that supports biotechnology companies and research institutes.”
Novartis also plans to build two new manufacturing facilities in Texas and Florida, which are not yet decided. In addition, the site of Carlsbad, Indiana, and New Jersey is expanded to focus on Radioligand Therapy Manufacturing, which is a type of radiation cancer treatment.
Novartis mentioned earlier It has invested more than $ 40 million in the Carlsbad facility, which is 10,000 square feet and will create more than 30 local jobs.
The company’s San Diego County location also includes Surrento Valley site of DTX Pharma. Biotechnology acquired in 2023 -Genomics Institute of Carlsbad’s laboratory and torrey pines novartis research foundation.
In July, Novartis announced a closed plan. One of the San Diego Research sites As part of a wide range of restructuring in the drug development sector, at the mid -2012 campus point drive.
At that time, Novartis spokesman said that the facility was being closed, but the company said in San Diego that it would continue to study with a team of about 580 employees.
Novartis said in it 2024 Annual Report As of December 31, he hired 75,883 people and scored about $ 11.9 billion.
UT staff writer Lori Weisberg contributed to this report.
Original publication:
